Fig. 5

Inhibiting EDI3 with dipyridamole, alone or in combination with HER2-targeting therapy in ER-HER2 + tumours in mice. Viability (RFU) after treating A, SKBR3 and B, HCC1954 cells with 25 µM (left panel) or 50 µM (right panel) dipyridamole with and without 0.1 µM lapatinib. C, Overview of in vivo experimental plan in CD1 nude mice. Mice with HCC1954 subcutaneous tumours were treated with dipyridamole, lapatinib or the combined treatment on a 5-days on/2-days off schedule for 4 weeks and the effect of treatment on tumour D, size, E, weight, and F, volume relative to vehicle control were examined. All in vitro data are mean ± SE of three independent experiments. Measurements (E–F) represent the average tumour weight and volume of four to six mice per condition. (*, P < 0.05; **, P < 0.01; ***, P < 0.001, ns, not significant). RFU, relative fluorescence units